European Society of Human Reproduction and Embryology (ESHRE) 40th Annual Meeting

Amsterdam, The Netherlands 07 July 2024 - 10 July 2024

Familial endocrine diseases may increase risk of pregnancy losses

13 Sep 2024 by

Having close family members with endocrine diseases, including type 2 diabetes (T2D), thyroid diseases, and polycystic ovary syndrome (PCOS), appears to increase the risk of pregnancy losses in a first-of-a-kind study presented at ESHRE 2024.

Familial endocrine diseases may increase risk of pregnancy losses

13 Sep 2024

Less risk, same benefit with relugolix combination vs monotherapy for endometriosis-related pain

05 Aug 2024 by

In the treatment of women with endometriosis-associated pain, relugolix combination has a risk-benefit profile that is more favourable than that of monotherapy, due to the latter contributing to increased vasomotor symptoms and substantial bone mineral density (BMD) loss, as shown in a study.

Less risk, same benefit with relugolix combination vs monotherapy for endometriosis-related pain

05 Aug 2024

IVIG plus prednisolone does not help improve chances of pregnancy

04 Aug 2024 by

The use of intravenous immunoglobulin (IVIG) plus prednisolone does not appear to increase conception rates among women with recurrent pregnancy loss who are undergoing assisted reproductive technology (ART), according to a study.

IVIG plus prednisolone does not help improve chances of pregnancy

04 Aug 2024

One jab of corifollitropin alfa equipotent to daily 300 IU of follitropin beta

02 Aug 2024 by

In a combined analysis of 3 phase III randomized trials presented at ESHRE 2024, a single dose of 150 µg or 100 µg of corifollitropin alfa is found to provide an ovarian response equivalent to daily doses of 300 IU or 297 IU of follitropin beta, respectively, during a single IVF cycle

One jab of corifollitropin alfa equipotent to daily 300 IU of follitropin beta

02 Aug 2024

Ovarian hyperstimulation syndrome ups risk of pregnancy complications

01 Aug 2024 by

Women with ovarian hyperstimulation syndrome (OHSS) are at higher risk of experiencing postpartum haemorrhage, large birthweight, neonatal respiratory distress syndrome, and intraventricular haemorrhage, suggests a study presented at ESHRE 2024.

Ovarian hyperstimulation syndrome ups risk of pregnancy complications

01 Aug 2024

Infertile women may benefit from oil-based contrast during HSG

01 Aug 2024 by

Hysterosalpingography (HSG) with an oil-based contrast medium yields a significantly higher rate of ongoing pregnancy and live birth than HSG with a water-soluble contrast medium, according to a study presented at ESHRE 2024.

Infertile women may benefit from oil-based contrast during HSG

01 Aug 2024

Is it unsafe to use GLP-1 RAs in early pregnancy?

31 Jul 2024 by

Exposure to GLP-1 receptor agonist (RA) treatment during early pregnancy does not appear to increase the risk of complications in pregnant women, as shown in a study presented at ESHRE 2024.

Is it unsafe to use GLP-1 RAs in early pregnancy?

31 Jul 2024

Dual trigger as good as GnRHa alone trigger for mature oocyte retrieval

27 Jul 2024 by

Dual triggering with gonadotropin-releasing hormone agonist (GnRHa) and human chorionic gonadotropin (hCG) was not superior to GnRHa alone in terms of mature oocyte retrieval for elective fertility preservation, according to a study presented at ESHRE 2024.

Dual trigger as good as GnRHa alone trigger for mature oocyte retrieval

27 Jul 2024

Air pollution detrimental to IVF success

26 Jul 2024 by

A study presented at ESHRE 2024 shows that increased exposure to fine particulate matter (PM2.5 and PM10) air pollution prior to oocyte collection (OPU) or frozen embryo transfer (FET) during in vitro fertilization (IVF) is associated with a reduction in live birth rates (LBRs) in subsequent FETs.

Air pollution detrimental to IVF success

26 Jul 2024

Novel pill keeps hopes up in infertile women ≤40 years undergoing IVF/ICSI

25 Jul 2024 by

In the phase II OXOART2 trial presented at ESHRE 2024, the first-in-class, non-hormonal, oral agent OXO-001 increases implantation and pregnancy rates in infertile women ≤40 years undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

Novel pill keeps hopes up in infertile women ≤40 years undergoing IVF/ICSI

25 Jul 2024